Tag: PQ Bypass

PQ Bypass announces US$60 million in financing for PAD treatment

Medical device company PQ Bypass has entered into an agreement that provides for up to an aggregate of US$60 million in equity financing, led...

DETOUR I 12-month data show promising durability of bypass system

Results from the DETOUR I trial evaluating the DETOUR System (PQ Bypass) for percutaneous bypass showed promising 12-month durability for patients with extremely long...

First patient treated in DETOUR II IDE trial

PQ Bypass has announced the enrolment of the first patients in the pivotal DETOUR II trial in the USA. The trial is a prospective,...

PQ Bypass receives IDE approval to initiate pivotal DETOUR II clinical...

PQ Bypass has received conditional approval of its investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate the pivotal...

PQ Bypass reports positive results for Detour system in patients with...

A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour system for treating long-segment (>25cm)...

PQ Bypass announces CE mark for Detour percutaneous bypass technologies

PQ Bypass has announced CE mark approval for a trio of proprietary devices: the Torus stent graft system, PQ Snare, and PQ Crossing Device,...

Percutaneous bypass using femoral vein could be “an important step” in...

In a first-time data release, Dierk Scheinert presented six-month outcomes from the DETOUR trial of percutaneous bypass in long segment femoropopliteal occlusions at the...

Positive safety and efficacy results from PQ Bypass DETOUR I study...

PQ Bypass has announced that the DETOUR I trial has met its primary safety and efficacy endpoints. The data were presented by Dierk Scheinert,...